References
- Chrysant SG. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular diseases and hypertension. Curr Hypertens Rep. 2013; 15(5): 475–483.
- Whittaker C. Phosphodiesterase type 5 inhibitors and erectile dysfunction. S Afr Fam Pract. 2010; 52(3): 207–211.
- Kukreja RC, Salloum FN, Das A, et al. Emerging new uses of phosphodiestrase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol. 2011; 16(4): 30–35.
- Schwartz BG, Levine LA, Comstock G, et al. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012; 59(1): 9–15.
- Ferguson JE, Carson CC. Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: current information and new horizons. Arab J Urol. 2013; 11: 222–229.
- Hellstrom WJG, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double blind, 26-week placebo-controlled pivotal trial. Urology. 2003; 61 Suppl 4A: 8–14.
- Bayraktar Z, Atun I. Prevalence of self-reported erectile dysfunction among urological causes in Turkish men. Urol J. 2011; 8(3): 214–220.
- Brenner GM, Stevens CW. Cholinergic receptor agonists: drugs that augment effects of acetylcholine. Pharmacology. 3rd ed. Philadelphia: WB Saunders Company; 2010.
- Moote R, Attridge RL, Levine DJ. Pulmonary arterial hypertension. In: DiPiro JT, Talbert RL, Yee GC, et al, editors. 8th ed. Pharmacotherapy: a pathophysiological approach. New York: McGraw-Hill, 2011; p. 497–508.
- Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res. 2007; 101(11): 1084–1095.
- Montani D, Chaumais M, Savale L, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther. 2009; 26(9): 813–825.
- Lee M. Erectile dysfunction. In: DiPiro JT, Talbert RL, Yee GC, et al. 8th ed. Pharmacotherapy: a pathophysiological approach. New York: McGraw-Hill, 2011; p. 1437–1454.
- Rossiter D, editor. South African medicines formulary. 12th ed. Cape Town: Health and Medical Publishing Group; 2012.
- Salloum FN, Chau VQ, Hoke NN, et al. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase G-dependent generation of hydrogen sulfide. J Am Heart Assoc. 2009; 120: S31–S36.
- Ahmad N, Wang Y, Ali AK, Ashraf M. Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury. Am J Physiol, Heart Circ Physiol. 2009; 297(1): 387–391.
- Sussman DO. Pharmacokinetics, pharmacodynamics and efficacy of phsphodiesterase type 5 inhibitors. J Am Osteopath Assoc. 2004; 104(3 Suppl 4): S11–S15.
- Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitor for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013; 63(5): 902–912.